Ranked by market caps dated April 12, 2006. NOTE: TEDG currently has one of lowest market caps at $41 million for this sector group.
GNBT = $235 million HEB = $180 million SVA = $158 million STTK = $68.9 million TEDG = $41 million
RANK BY FISCAL 2005 REVENUES
Revenues for the trailing 12 months. NOTE: TEDG did the most revenue at $10 million for this sector group. Investors are advised to check current SEC filings as some of these numbers may have changed over the running quarter.
TEDG = $10 million SVA = $6.8 million HEB = $1 million STTK = $756k GNBT = $260k
RANK BY SHARE PRICE
NOTE: TEDG is trading for the lowest price in this sector group as of closing bell on April 12, 2006.
HEB = $2.95 GNBT = $2.65 SVA = $1.95 STTK = $0.64 TEDG = $0.50
SHARE PRICE IF TEDG TRADED AT COMPETITOR MARKET CAPS
GNBT ($235 mrkt cap) = $2.86 a share HEB ($180 mrkt cap) = $2.19 a share SVA ($158 mrkt cap) = $1.95 a share STTK ($68.9 mrkt cap) = $0.84 a share
TEDG (current price) = $0.50
The best comparison should be with SVA, as it's also a vaccine research company based out of China like TEDG, and did around $6.8 million in revenues for fiscal 2005. We should give SVA a premium above TEDG for being on the AMEX exchange, lets say 50% to be conservative. SVA is currently trading at $1.95 share price. If TEDG were trading at say $1.30 a share, then 50% above that price is SVA at $1.95. (50% of $1.30 = .65 + $1.30 = $1.95 or SVA current share price). Note: TEDG did almost 50% more in sales revenue as compared to SVA for fiscal 2005. TEDG should be trading, fairly, around $1.30 per share compared to others in the bird flu sector.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.